Immix Biopharma Inc

NASDAQ IMMX

Data sourced from

and

Daily

Download Data

Immix Biopharma Inc Market Capitalization on June 03, 2024: USD 51.51 M

Immix Biopharma Inc Market Capitalization is USD 51.51 M on June 03, 2024, a 58.29% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Immix Biopharma Inc 52-week high Market Capitalization is USD 142.56 M on December 15, 2023, which is 176.76% above the current Market Capitalization.
Immix Biopharma Inc 52-week low Market Capitalization is USD 31.27 M on June 07, 2023, which is -39.29% below the current Market Capitalization.
Immix Biopharma Inc average Market Capitalization for the last 52 weeks is USD 69.14 M.

NASDAQ: IMMX

Immix Biopharma Inc

CEO	Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date	Dec. 16, 2021
Location	United States
Headquarters	11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees	14
Sector	Healthcare
Industry	Biotechnology

Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Key trends